Kelun is a highly specialized innovative pharmaceutical group with annual sales revenue over 40 billion RMB, including more than 100 enterprises at home and abroad, Sichuan Kelun Pharmaceutical Co., Ltd; Sichuan Kelun Drug Research Institute Co., Ltd; Klus Pharma Inc. (Kelun, USA), Kelun KAZ Pharmaceutical Co., Ltd (Kelun, Kazakhstan); Sichuan Kelun Medicine Trade Co., Ltd, etc. In 2017, kelun ranked 155th in China's top 500 manufacturing enterprises, and comprehensive strength ranked top three in China's pharmaceutical industry.
Sichuan Kelun Pharmaceutical Co., ltd. was listed on the Shenzhen Stock Exchange in June 2010. At the same time, Kelun immediately launched the plan of 10 billion RMB industrial investment and began to implement the development strategy of "three development driving engines and innovative growth".The first engine is through continuous industrial upgrading and product variety adjustment, to maintain Kelun's absolute leading position in the field of IV infusion; The second engine is to build the competitive advantage of the whole antibiotics industrial chain from intermediates, APIs to formulations through the innovative development and utilization of high-quality natural resources. The third engine is to accumulate the ultimate driving force for the enterprise development through the construction of research and development system and diversified technological innovation.
In the field of IV infusion, kelun has achieved comprehensive industrial upgrading, with the profitability of high-end manufacturing and new materials, and occupied the strategic highland of technical innovation and quality benchmark. Kelun has established a closed liability system from drug research and development, manufacturing, logistics to end use, which ensures product quality and safety. The leading products have been exported to more than 40 countries and regions with high reputation. Kelun’s innovated self-collapsible PP infusion bottle has more than 20 patents, won the national science and technology prize. Compared with traditional infusion, it has higher safety and cost-effective performance, and has great application value in reducing energy consumption and protecting environment. It represents the developmental direction of infusion products in China and profoundly changes the industrial pattern.
After basically completing the horizontal integration in the field of infusion, Kelun initiated the vertical integration in the field of antibiotics and carried out the strategic layout of "the whole antibiotic industry chain" nationwide. The Yili Chuanning Biotechnology Co., Ltd was established, producing erythromycin thiocyanate and cephalosporin series of intermediates.Through research and development, upgrading, optimization, innovative cooperation and introduction of advanced technology and equipment at home and abroad, "the integration and application of biological fermentation antibiotic production end gas treatment technology" won the first prize of scientific and technological progress of Xinjiang Uygur Autonomous Region. The comprehensive competitive advantage of the whole industrial chain of kelun antibiotics has become the unshakable in the industry.
Since its establishment, Kelun has invested billions in R&D and innovation, established national postdoctoral research stations and academician workstations, and won 13 national key new products, 7 "12th five-year plan major new drug innovation" projects, 1 national science and technology support plan and 1 national science and technology assistance project support. Up to now, Kelun has applied more than 3,000 patents and obtained more than 2,000 patent authorizations. It has successively started the research and development for more than 300 major drugs in the fields of tumor, bacterial infection, parenteral nutrition and other diseases, and has achieved a breakthrough in the licensing of innovative patents to developed countries.
To make full use of the drug research talent resources at home and abroad, Kelun established the research system center on Chengdu institute, uniting with the Suzhou branch, Tianjin branch and US institute branch, forming a new research pattern of leading by domestic positive research, assisting by overseas techniques, reaching the first level of Chinese medicine enterprise innovation ability.
With the enterprise objective "Pursue Truth in Science and Kindness in Ethics", Kelun donated over one hundred million for the social public welfare and charity, presenting Kelun’s sense of social responsibility, exhibiting a good and healthy developmental image of private enterprises under the condition of market economy.